Bloqcube and NTT DATA Partner to Deliver Blockchain-Driven Management Solutions
BloqCube, a developer of a proprietary integrated clinical trial and financial management system employing innovative blockchain technology, and NTT DATA announced an alliance to benefit the healthcare and life sciences industry.
BloqCube will bring to the partnership its pioneering technology that speeds up clinical trials, by enhancing efficiencies of multiple related processes while retaining strong data security. NTT DATA will provide its expertise in enterprise-scale domain consulting, application implementation and integration services through the company’s healthcare and life sciences business consulting and blockchain technology competencies.
BloqCube uses proprietary algorithms to automate what is typically a laborious process of monitoring clinical trial sites (hospitals, treatment centers) and verifying data. Its C2TA technology delivers real-time accounting transaction records of payments and financial planning to clinical trial management. BloqCube is the first company to offer a fully integrated clinical management system leveraging blockchain technology to ensure data security and integrity while accelerating clinical trials and cutting costs.
BloqCube will benefit from NTT DATA’s experience in accelerating value-based healthcare, maximizing efficiency and delivering flexible solutions to achieve accuracy and customer satisfaction.
BloqCube CEO Rama K. Rao stated, “We are delighted to work with NTT DATA as both our organizations are clearly focused on improving patient outcomes. NTT DATA has a broad client base in the healthcare and life sciences industry that will be able to take advantage of our first-in-class clinical trial and financial management technology while BloqCube clients will benefit from NTT DATA’s enterprise-scale services.”
BloqCube participated in the New Jersey Innovation Institute (NJII), Health IT Connections program that connects health IT innovators with leading healthcare corporations, like NTT DATA. NJII’s Health IT Connections program is funded in part from JPMorgan Chase’s Small Business Forward initiative.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
